Navigation Links
Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
Date:5/11/2009

SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that Jay Hagan has joined the organization as Senior Vice President of Corporate Development and Strategy.

"Jay brings over 15 years of biotechnology operating and business development experience in a variety of roles including leadership of a significant number of important transactions. We are excited to add someone of Jay's breadth of experience to the Orexigen executive team, " said Michael Narachi, President and Chief Executive Officer. "His solid background will be invaluable as we focus on partnership opportunities and position the organization to successfully manage our operations, continue our development activities and execute on our commercialization plans for Contrave(R) and Empatic(TM)."

In his role, Jay will lead corporate development at Orexigen, notably focusing on partnership opportunities and commercialization strategy for lead products Contrave (naltrexone sustained release (SR)/bupropion SR), which is on track for an NDA submission to the FDA in the first half of 2010, and Empatic (zonisamide SR/bupropion SR), which is in the later stages of Phase 2 clinical development.

"I'm incredibly excited to join the Orexigen team at this pivotal time for the Company," said Jay. "Orexigen possesses a unique opportunity among small biotechnology companies. I look forward to leveraging my extensive experience in corporate and partnership strategy to further the Company's business development efforts."

Prior to joining Orexigen, Jay was a Partner at Groundswell Advisors, a biotechnology consulting firm, providing guidance and operational execution in corporate strategy, commercialization, financing and partnership op
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
2. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
3. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
4. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
5. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
6. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
11. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Berkshire Corporation, the world leader ... the release of the ValuSeal® IonX™ cleanroom wiper, ... containment in critical processing applications. , Recommended for ... environments, ValuSeal® IonX™ is a laser sealed edge ... continues Berkshire’s innovative focus on meeting new challenges ...
(Date:10/25/2014)... ROCKVILLE, Md. , Oct. 24, 2014  RegeneRx Biopharmaceuticals, ... on data presented at the Fourth International Symposium on ... , Italy.  "When thymosin beta ... was injected into the peritoneal cavity in a rodent ... vessels and throughout the brain parenchyma (the functional tissue ...
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... , ... Have Clear Goals, Timeline and Roles , ... Canberra, Australia (Vocus) October 27, 2009 -- Global food security, ... fully achieved through well-designed and executed public and private partnerships, William S. Niebur ...
... Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... its 33rd U.S. Patent, # 7,608,257, entitled "Sensitization ... Virus." The patent claims cover methods of using ... to treat patients that are refractory to those ...
... Md., Oct. 27 Precision Antibody(TM) has ... of the National Cancer Institute (NCI),s Clinical Proteomic Technologies ... number and standardizing the quality of monoclonal antibody reagents ... is the result of a third solicitation for contract ...
Cached Biology Technology:Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 2Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 3Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 3
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... illnesses have triggered calls for more regulation along ... University of Minnesota this week will explore the ... "How Safe is our Food Supply? Expectations, Technology, ... p.m. Wednesday, April 1, at Coffman Memorial Hall, ...
... GAITHERSBURG, Md.Researchers at the Commerce Department,s National Institute ... have capitalized on a process for manufacturing integrated ... level and used it to develop a method ... with complex three-dimensional surfaces. As described ...
... Swedish medical university Karolinska Institutet (KI) have constructed a mathematical ... increase the understanding of the capacity of the working memory ... interact. One of the findings they have made with this ... that restricts the number of items we can normally store ...
Cached Biology News:NIST-Cornell team builds world's first nanofluidic device with complex 3-D surfaces 2NIST-Cornell team builds world's first nanofluidic device with complex 3-D surfaces 3NIST-Cornell team builds world's first nanofluidic device with complex 3-D surfaces 4Computer simulations explain the limitations of working memory 2